公开(公告)号：US20100068249A1

公开(公告)日：2010-03-18

申请号：US12621595

申请日：2009-11-19

申请人： John R. Hart ,  Steven C. Anderson ,  Melissa A. Vanblaricom ,  Ellen R. Bosl

发明人： John R. Hart ,  Steven C. Anderson ,  Melissa A. Vanblaricom ,  Ellen R. Bosl

IPC分类号： A61K31/445 ,  A61K9/70 ,  A61P25/00

CPC分类号： A61K9/7061 ,  A61K9/7092 ,  A61K31/4468 ,  A61K31/485

摘要： The present invention comprises a transdermal dosage form comprising an active agent component having a skin contacting surface, an adverse agent component, and a barrier. The dosage form comprises at least one channel passing between proximal and distal surfaces of the active agent component. The barrier is interposed between the active agent component and the adverse agent component. In one aspect, the barrier is permeable to selected solvents and impermeable to diffusion of active and adverse agents in the absence of said solvent. In another aspect, the barrier is discontinuous, impermeable to diffusion of active and adverse agents, and the dosage form comprises at least one channel passing between the skin-contacting surface and the adverse agent component.

摘要翻译： 本发明包括透皮剂型，其包含具有皮肤接触表面的活性剂组分，不利剂组分和屏障。 所述剂型包含至少一个在活性剂组分的近端和远端表面之间通过的通道。 阻挡层介于活性剂组分和不利剂组分之间。 在一个方面，所述屏障对于所选择的溶剂是可渗透的，并且在不存在所述溶剂的情况下不可渗透活性和不利剂。 在另一方面，屏障是不连续的，不渗透活性剂和不利剂的扩散，并且剂型包含通过皮肤接触表面和不利剂组分之间的至少一个通道。